US EditionTeva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® ...
- In May 2025, Teva Pharmaceuticals shared real-world clinical and treatment data on UZEDY for schizophrenia during the Psych Congress Elevate Annual Meeting.
- This presentation followed previous research highlighting UZEDY’s development as an extended-release injectable risperidone compared to daily oral antipsychotics to improve adherence and outcomes.
- Data showed patients using UZEDY had lower relapse rates, fewer hospital visits, shorter stays, and reduced all-cause healthcare resource utilization than those on oral treatments.
- Phase 3 SOLARIS trial data reported no cases of post-injection delirium/sedation syndrome in participants receiving TEV-'749, a monthly injectable olanzapine formulation presented at the same meeting.
- These findings suggest that long-acting injectable formulations like UZEDY and TEV-'749 may improve treatment adherence and reduce healthcare burdens for adults with schizophrenia.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
All
Left
10
Center
1
Right
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® ...
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral optionsLatest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after…
·Bakersfield, United States
Read Full Article
WellandTribune.ca+9 Reposted by 9other sources
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral optionsLatest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after…
Coverage Details
Total News Sources11
Leaning Left10Leaning Right0Center1Last UpdatedBias Distribution91% Left
Bias Distribution
- 91% of the sources lean Left
91% Left
L 91%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage